Skip to main content

Table 2 Baseline features and symptom outcome in ROM patients suffering from MDD

From: The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice

  All MDD patients (n=598) Patients who received psychotherapy only (n=80)
Age (in years) 39.3 (SD 11.3) 36.2 (SD 10.8)
Gender (% female) 66.7% (n= 399) 73.8% (n=59)
MADRS pre treatment 25.9 (SD 6.5) 24.1 (SD 6.0)
MADRS post treatment 18.2 (SD 9.4) 16.5 (SD 9.1)
Treatment outcome   
Within-Group Effectsize1 1.16 1.28
Proportion of responders2 29.1% 35.0%
Proportion of remitters3 22.6% 27.5%
Ethnicity   
Netherlands 84.8% 76.4%
Turkey/Morocco 5.1% 5.5%
Suriname/Antilles 3.1% 4.2%
Other 7.0% 13.9%
Marital Status   
Married/Cohabitating 52.8% 44.4%
Divorced/Widowed 16.6% 22.2%
Single/LAT 30.0% 33.3%
Employment Status   
Employed 34.3% 34.7%
Not Employed 26.1% 34.7%
Sickness Benefit 39.0% 30.6%
Retired 0.6% 0%
Educational level   
Low 12.3% 9.7%
Intermediate low 33.1% 23.6%
Intermediate high 38.4% 40.3%
High 16.2% 26.4%
  1. Caption:
  2. 1 Within Group Effectsize is a definition of treatment outcome often used in PETs and defined as: the extent of improvement (Δ MADRS pre- and post treatment within the group under investigation) adjusted for the standard deviation pre treatment.
  3. 2 Response is defined as a 50% reduction of symptoms on the MADRS.
  4. 3 Remission is defined as MADRS≤10.